Invesco Ltd. Buys 11,343 Shares of Kymera Therapeutics, Inc. $KYMR

Invesco Ltd. boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 36.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 42,075 shares of the company's stock after purchasing an additional 11,343 shares during the quarter. Invesco Ltd. owned approximately 0.06% of Kymera Therapeutics worth $1,152,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Northern Trust Corp raised its holdings in Kymera Therapeutics by 14.0% in the fourth quarter. Northern Trust Corp now owns 437,833 shares of the company's stock worth $17,614,000 after purchasing an additional 53,658 shares in the last quarter. Ameriprise Financial Inc. bought a new position in Kymera Therapeutics in the fourth quarter worth $344,000. GAMMA Investing LLC raised its holdings in Kymera Therapeutics by 3,851.5% in the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock worth $183,000 after purchasing an additional 6,509 shares in the last quarter. Millennium Management LLC raised its holdings in Kymera Therapeutics by 205.0% in the fourth quarter. Millennium Management LLC now owns 115,918 shares of the company's stock worth $4,663,000 after purchasing an additional 77,912 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Kymera Therapeutics by 9.0% during the 1st quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock valued at $1,914,000 after buying an additional 5,771 shares in the last quarter.

Kymera Therapeutics Trading Up 3.1%

KYMR stock traded up $1.31 during midday trading on Friday, hitting $43.51. The company's stock had a trading volume of 575,311 shares, compared to its average volume of 709,469. The company has a market cap of $3.11 billion, a PE ratio of -12.54 and a beta of 2.17. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $53.27. The firm's 50-day moving average is $43.38 and its 200-day moving average is $36.99.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The business had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The business's revenue was down 55.1% compared to the same quarter last year. During the same period last year, the company posted ($0.58) earnings per share. Analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bros. Advisors Lp Baker acquired 655,500 shares of the stock in a transaction that occurred on Monday, June 30th. The shares were acquired at an average cost of $44.00 per share, with a total value of $28,842,000.00. Following the transaction, the director owned 6,117,295 shares of the company's stock, valued at $269,160,980. The trade was a 12.00% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bvf Partners L. P/Il acquired 317,167 shares of the stock in a transaction that occurred on Monday, June 30th. The stock was acquired at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the transaction, the director directly owned 2,798,795 shares in the company, valued at $123,146,980. This represents a 12.78% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 16.01% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on KYMR shares. JPMorgan Chase & Co. raised their price objective on Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a research report on Tuesday, June 3rd. Wall Street Zen lowered Kymera Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. BTIG Research reaffirmed a "buy" rating and set a $59.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Bank of America raised Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective for the company in a research report on Monday, June 2nd. Finally, Stifel Nicolaus began coverage on Kymera Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $55.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $58.76.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.